PEAK6 LLC Lowers Position in Kenvue Inc. $KVUE

Posted by George Bondi on Jun 20th, 2026

PEAK6 LLC trimmed its holdings in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 88.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,154 shares of the company’s stock after selling 142,584 shares during the quarter. PEAK6 LLC’s holdings in Kenvue were worth $330,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Physician Wealth Advisors Inc. raised its stake in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares in the last quarter. Elyxium Wealth LLC purchased a new stake in shares of Kenvue during the 4th quarter valued at $26,000. MV Capital Management Inc. bought a new stake in shares of Kenvue during the 4th quarter worth $28,000. Reflection Asset Management purchased a new position in Kenvue in the fourth quarter worth $32,000. Finally, SBI Securities Co. Ltd. increased its stake in Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after acquiring an additional 1,027 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 0.3%

Shares of Kenvue stock opened at $18.17 on Friday. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $22.87. The company has a market cap of $34.88 billion, a P/E ratio of 21.37, a PEG ratio of 1.37 and a beta of 0.54. The company’s fifty day simple moving average is $17.54 and its two-hundred day simple moving average is $17.57.

Kenvue (NYSE:KVUE – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The firm had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. During the same period last year, the company posted $0.24 EPS. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. Research analysts anticipate that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were issued a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.6%. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of several research analyst reports. Citigroup dropped their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. UBS Group cut their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Argus raised Kenvue to a “hold” rating in a research note on Friday, March 6th. Finally, Barclays cut their target price on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $19.33.

Get Our Latest Stock Analysis on Kenvue

Insiders Place Their Bets

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 1.59% of the company’s stock.

Kenvue Profile

(Free Report)

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.